Free Trial

Grifols (GRFS) Competitors

Grifols logo
$9.94 +0.09 (+0.91%)
Closing price 07/24/2025 04:00 PM Eastern
Extended Trading
$10.04 +0.10 (+1.01%)
As of 06:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GRFS vs. BNTX, INSM, SMMT, TEVA, ITCI, GMAB, MRNA, RDY, VTRS, and QGEN

Should you be buying Grifols stock or one of its competitors? The main competitors of Grifols include BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.

Grifols vs. Its Competitors

Grifols (NASDAQ:GRFS) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Grifols presently has a consensus price target of $10.30, indicating a potential upside of 3.62%. BioNTech has a consensus price target of $136.58, indicating a potential upside of 19.21%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than Grifols.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Grifols
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00
BioNTech
0 Sell rating(s)
4 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.83

In the previous week, BioNTech had 2 more articles in the media than Grifols. MarketBeat recorded 7 mentions for BioNTech and 5 mentions for Grifols. Grifols' average media sentiment score of 0.75 beat BioNTech's score of 0.40 indicating that Grifols is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Grifols
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioNTech
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Grifols has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grifols$7.21B0.95$169.80M$1.178.50
BioNTech$2.98B9.25-$719.92M-$3.40-33.70

Grifols has a net margin of 0.00% compared to BioNTech's net margin of -27.37%. Grifols' return on equity of 0.00% beat BioNTech's return on equity.

Company Net Margins Return on Equity Return on Assets
GrifolsN/A N/A N/A
BioNTech -27.37%-3.94%-3.41%

15.5% of BioNTech shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Grifols has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.

Summary

Grifols beats BioNTech on 9 of the 16 factors compared between the two stocks.

Get Grifols News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRFS vs. The Competition

MetricGrifolsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.77B$2.77B$5.73B$9.47B
Dividend YieldN/A1.78%4.60%3.99%
P/E Ratio8.509.1227.9819.95
Price / Sales0.95736.18447.46100.93
Price / Cash10.52166.2336.5558.97
Price / Book0.735.228.655.90
Net Income$169.80M$30.99M$3.24B$258.42M
7 Day PerformanceN/A4.60%3.69%2.11%
1 Month Performance16.80%12.70%10.34%12.44%
1 Year Performance27.76%-0.48%34.36%19.55%

Grifols Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRFS
Grifols
3.8015 of 5 stars
$9.94
+0.9%
$10.30
+3.6%
+28.6%$6.77B$7.21B8.5023,822Upcoming Earnings
BNTX
BioNTech
1.4928 of 5 stars
$111.00
-1.7%
$137.91
+24.2%
+37.8%$26.68B$2.98B-32.656,772
INSM
Insmed
4.0761 of 5 stars
$101.89
+3.8%
$108.07
+6.1%
+39.1%$19.33B$381.03M-17.121,271Positive News
Analyst Forecast
Insider Trade
SMMT
Summit Therapeutics
3.2355 of 5 stars
$25.40
+1.6%
$34.67
+36.5%
+176.3%$18.86BN/A-74.70110Positive News
TEVA
Teva Pharmaceutical Industries
4.267 of 5 stars
$16.43
+0.2%
$24.71
+50.5%
-0.8%$18.84B$16.54B-14.2836,830Positive News
Upcoming Earnings
Gap Up
ITCI
Intra-Cellular Therapies
1.0348 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
4.0574 of 5 stars
$21.46
+0.3%
$37.80
+76.1%
-15.2%$13.77B$3.12B12.192,682Positive News
Gap Up
MRNA
Moderna
4.2558 of 5 stars
$32.87
-2.3%
$46.61
+41.8%
-71.2%$12.71B$3.24B-3.775,800Upcoming Earnings
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.8552 of 5 stars
$14.58
+0.4%
$16.95
+16.3%
-8.1%$12.17B$325.54B22.0827,811Earnings Report
VTRS
Viatris
2.4996 of 5 stars
$9.14
+0.2%
$10.40
+13.8%
-20.1%$10.73B$14.74B-2.8832,000
QGEN
Qiagen
3.7553 of 5 stars
$48.25
+0.3%
$49.40
+2.4%
+25.6%$10.73B$1.98B120.985,765Positive News
Analyst Revision

Related Companies and Tools


This page (NASDAQ:GRFS) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners